33942 Federal Register / Vol. 83, No. 138 / Wednesday, July 18, 2018 / Notices 

national security. The changes are as 

follows. 

I. Under AN.10 Organization, delete 

all of the components and replace with 

the following: 

A. Immediate Office of the Assistant 

Secretary for Preparedness and 

Response (ANA) 

B. Office of Biomedical Advanced 

Research and Development Authority 

(ANB) 

C. Office of the Principal Deputy 

Assistant Secretary (ANC) 

D. Office of the Deputy Assistant 

Secretary Incident Command and 

Control (ANG) 

II. Delete AN.20 Functions, in its 

entirety and replace with the following: 

Section AR.20 Functions. 

A. Immediate Office of the Assistant 

Secretary for Preparedness and 

Response: The Immediate Office of the 

Assistant Secretary for Preparedness 

and Response (IO/ASPR) is headed by 

the Assistant Secretary, who provides 

leadership and executive and strategic 

direction for the ASPR organization. 

The Assistant Secretary is the principal 

advisor to the Secretary on all matters 

related to Federal public health and 

medical preparedness and response for 

public health emergencies. The 

Assistant Secretary is responsible for 

carrying out ASPR’s mission and 

implementing the functions of ASPR. 

The IO/ASPR (1) ensures development 

and maintenance of liaison 

relationships with HHS operating and 

staff divisions and represents HHS at 

interagency meetings, as required; (2) 

establishes and maintains effective 

communications and outreach guidance 

and support for all external 

communications, including legislative 

and executive branch questions and 

inquiries, and serves as the principal 

advisor to the ASPR on all legislative 

strategies to fulfill the Office of the 

ASPR and the HHS mission under 

section 2811 and other relevant sections 

of the Public Health Service Act, as 

amended; (3) oversees advanced 

research, development and procurement 

of qualified countermeasures, security 

countermeasures and qualified 

pandemic or epidemic products; (4) 

coordinate with relevant federal officials 

to ensure integration of federal 

preparedness and response activities for 

public health emergencies; (5) manages 

correspondence control for the Assistant 

Secretary; and (6) coordinates the 

strategic and operational activities for 

public health preparedness response 

and recovery. 

B. Office of Biomedical Advance 

Research and Development Authority 

(ANB). The Office of Biomedical 

Advanced Research and Development 

Authority (BARDA), established in 

April 2007 in response to the Pandemic 

and All-Hazards Preparedness Act of 

2006, serves preparedness and response 

roles to provide medical 

countermeasures (MCM) in order to 

mitigate the medical consequences of 

chemical, biological, radiological, and 

nuclear (CBRN) threats and agents and 

emerging infectious diseases, including 

pandemic influenza. BARDA executes 

this mission by facilitating research, 

development, innovation, and 

acquisition of MCM and expanding 

domestic manufacturing infrastructure 

and surge capacity of these MCM. 

BARDA is headed by a Deputy 

Assistant Secretary, and includes the 

following components: 

• Division of Influenza (ANB1) 

• Division of Emerging Infectious 

Diseases (ANB2) 

• Division of Chemical, Biological, 

Radiological and Nuclear Threats 

(ANB3) 

• Division of Strategic Science and 

Technology (ANB4) 

• Division of Regulatory and Quality 

Affairs (ANB5) 

• Division of Research, Innovation and 

Ventures (ANB6) 

C. Office of the Principal Deputy 

Assistant Secretary (ANC). The Office of 

the Principal Deputy Assistant Secretary 

(OPDAS) is responsible for providing a 

well-integrated infrastructure that 

supports the Department’s capabilities 

to prevent, prepare for, respond to and 

recover from natural public health and 

medical threats and emergencies. 

OPDAS leads the preparedness and 

response activities required to 

coordinate public health and healthcare 

response systems and activities with 

relevant federal, state, tribal, territorial, 

local, and international communities 

under the National Response 

Framework and Emergency Support 

Annexes #8, #6 and #14. OPDAS is 

responsible for the execution of 

business management operations and 

managing coordination. OPDAS 

provides for the facility, logistics, 

information technology and 

infrastructure support services 

necessary to maintain day-to-day 

operations of ASPR, including functions 

of Human Resources, Organization and 

Employee Development, Ethics, United 

States Public Health Service (USPHS) 

liaison, acquisitions management, 

contracts, grants, and all financial 

planning and analysis. 

The Office of the Principal Deputy 

Assistant Secretary is headed by the 

Principal Deputy Assistant Secretary, 

and includes the following components: 

• Division of Management Finance and 

Human Capital (ANC1) 

• Division of Emergency Management 

and Medical Operations (ANC2) 

• Division of Resource Management 

(ANC3) 

D. Deputy Assistant Secretary 

Incident Command and Control (ANG): 

The Deputy Assistant Secretary (DAS/ 

ICC) is responsible for the policy 

development, planning analysis, 

requirements and strategic planning. 

DAS/ICC manages and operates the HHS 

Secretary’s Operation Center (SOC), 

intelligence, security, information 

management and is also responsible for 

the HHS Continuity of Operations 

(COOP) and the development of the 

ASPR COOP Plan. The Office of the 

Assistant Secretary Incident Command 

and Control (DAS/ICC) is headed by the 

Deputy Assistant Secretary Incident 

Command and Control, and includes the 

following components: 

• Division of Security Intelligence and 

Information Management 

• Division of Strategy, Policy, Planning 

and Requirements 

III. Delegations of Authority. All 

delegations and redelegations of 

authority made to officials and 

employees of affected organizational 

components will continue in them or 

their successors pending further 

redelegation, provided they are 

consistent with this reorganization. 

Alex M. Azar II, 

Secretary. 

[FR Doc. 2018–15310 Filed 7–17–18; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 138 / Wednesday, July 18, 2018 / Notices 33943 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Sleep Apnea 

Treatment With Positive Airway Pressure for 

Prevention of Diabetes Mellitus. 

Date: July 27, 2018. 

Time: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7345, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Bariatric SurgeryRelated Applications. 

Date: July 30, 2018. 

Time: 2:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Paul A. Rushing, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7345, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8895, 

rushingp@extra.niddk.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Type 1 Diabetes 

Small Business Applications. 

Date: August 6, 2018. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Ryan G. Morris, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7015, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–4721, 

ryan.morris@nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK–17–035 

Microphysiological Systems (MPS) for 

Modeling Diabetes (UG3/UH3). 

Date: August 7, 2018. 

Time: 11:30 a.m. to 3:30 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Ann A. Jerkins, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7119, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, 301–594–2242, 

jerkinsa@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Time-Sensitive 

Obesity Research. 

Date: August 8, 2018. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Michele L. Barnard, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7353, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, (301) 594–8898, 

barnardm@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK–17–030 

Advancement of Cell Replacement Therapies 

for Type 1 Diabetes (R43/R44). 

Date: August 8, 2018. 

Time: 12:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Ann A. Jerkins, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7119, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, 301–594–2242, 

jerkinsa@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK–R01 

Telephone Review. 

Date: August 10, 2018. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Xiaodu Guo, MD, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7023, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: July 12, 2018. 

Ronald J. Livingston, Jr., 

Program Analyst, Office of Federal Advisory 

Committee Policy/ 

[FR Doc. 2018–15280 Filed 7–17–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel, Center 

for Genetic Studies (7797). 

Date: July 25, 2018. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Gerald L. McLaughlin, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, NIH, DHHS, 6001 

Executive Blvd., Room 4238, MSC 9550, 

Bethesda, MD 20892–9550, 301–827–5819, 

gm145a@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program No.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: July 12, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–15279 Filed 7–17–18; 8:45 am] 

BILLING CODE 4140–01–P 


amozie on DSK3GDR082PROD with NOTICES1